Any current/future new fundraising through debt or equity?

The company has raised Non-Convertible Debentures (NCDs) recently and reorganized its debt to avoid any repayment burden for over two years. There is an option to start pre-paying the debt after one year based on cash flows. The finance cost is currently higher but is expected to come down as the company improves cash flow and explores strategic options. The company is contemplating various strategic options, including possible equity infusion, to generate cash that can be used to reduce the finance cost. Regarding equity fundraising, the company is actively evaluating prospects and is in touc

Any current/future capex/capital investment/strategic investment?

INR 64 crore capex was spent in the first half of FY24, with approximately INR 52 crore invested in an upcoming Albumin manufacturing facility (Page 6). The company is actively streamlining R&D expenditures and focusing on monetization to improve cash flow without compromising product quality (Page 2). Investments have been made to upgrade API facilities to offer peptide, polymer, and CDMO services, aiming for value creation despite associated gestation periods (Page 2). Ongoing strategic initiatives include scaling up complex product pipelines and extending existing products to new countries

Future growth expectations in sales/revenue/volumes?

The company expects robust revenue growth driven by a mix of higher-margin therapies and new product platforms. Consolidated revenues for Q2 FY24 stood at INR 315 crore, growing 20% sequentially and 18% year-on-year. For H1 FY24, revenues increased 8% to INR 577 crore, with EBITDA growth of 148% year-on-year. Growth is supported by new complex products launching over the next two years and expansion into new countries. Active efforts to streamline operating expenses and R&D spends aim to improve cash flows without compromising growth. The biologics segment and products like topical lotion for

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth: Q2 FY24 revenues grew 18% YoY and 20% sequentially, indicating a strong growth trajectory. EBITDA improved significantly to INR 62 crore in Q2 FY24, up from INR 16.6 crore last year, showing enhanced profitability. Positive PAT (INR 1.6 crore in Q2 FY24 vs. a loss last year) suggests return to profitability. For H1 FY24, revenues increased 8% YoY with a 148% growth in EBITDA, supporting sustained growth momentum. Monetization through licensing and collaborations expected to provide consistent and meaningful revenue streams over next few quarters. Pipeline of complex products an

Shilpa Medicare LtdQ2 FY24Pharmaceuticals & Biotechnology

Shilpa Medicare Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹876.2P/E: 60.2Market Cap: ₹17.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company expects robust revenue growth driven by a mix of higher-margin therapies and new product platforms.
Consolidated revenues for Q2 FY24 stood at INR 315 crore, growing 20% sequentially and 18% year-on-year.
For H1 FY24, revenues increased 8% to INR 577 crore, with EBITDA growth of 148% year-on-year.
Growth is supported by new complex products launching over the next two years and expansion into new countries.
Active efforts to streamline operating expenses and R&D spends aim to improve cash flows without compromising growth.
The biologics segment and products like topical lotion for alopecia and Adalimumab are positioned for higher market traction, especially in India and Rest of World (ROW).
The global alopecia market is estimated at $8.2 billion with 9% CAGR, presenting significant future volume opportunities.
Licensing revenues from pipeline products provide additional, though variable, sources of income over the next few quarters.
The company is focused on balancing development costs with monetization potential to sustain growth.

Margin guidance

Category 3

Revenue growth: Q2 FY24 revenues grew 18% YoY and 20% sequentially, indicating a strong growth trajectory.
EBITDA improved significantly to INR 62 crore in Q2 FY24, up from INR 16.6 crore last year, showing enhanced profitability.
Positive PAT (INR 1.6 crore in Q2 FY24 vs. a loss last year) suggests return to profitability.
For H1 FY24, revenues increased 8% YoY with a 148% growth in EBITDA, supporting sustained growth momentum.
Monetization through licensing and collaborations expected to provide consistent and meaningful revenue streams over next few quarters.
Pipeline of complex products and extension in new geographies likely to drive future earnings.
Business focus on higher margin therapies, cost optimization, and efficient R&D spending to improve operating margins.
Net debt management and potential equity inflows expected to reduce finance costs, supporting profitability expansion.
Overall outlook: robust improvement in cash flows and sustainable earnings growth over medium term.

See what Shilpa Medicare Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company has raised Non-Convertible Debentures (NCDs) recently and reorganized its debt to avoid any repayment burden for over two years.
There is an option to start pre-paying the debt after one year based on cash flows.
The finance cost is currently higher but is expected to come down as the company improves cash flow and explores strategic options.
The company is contemplating various strategic options, including possible equity infusion, to generate cash that can be used to reduce the finance cost.
Regarding equity fundraising, the company is actively evaluating prospects and is in touch with the board to decide the way forward on the rights issue.
No concrete updates were provided on timing or confirmation of any new equity fundraising; shareholders will be updated at the appropriate time.

Order book

The transcript provided does not explicitly mention the current or expected order book or pending orders details for Shilpa Medicare Limited. However, some relevant insights related to business outlook and product pipeline include: - The company has several complex products lined up over the next two years, including extensions of existing products into new countries. - They are actively engaged with clients for peptide business and introducing polymer and CDMO services, expecting firm commitments as exhibit batches are shared. - The company is focusing on monetization and licensing strategies for products in development, which may contribute to future order inflows. - Marketing authorizations and product approvals in markets like Mexico, UK, and plans for EU and US expansions indicate ongoing opportunities. - The company is emphasizing cost control and cash flow improvement to support business growth. No direct numeric or specific order book value was disclosed in the transcript.

See what Shilpa Medicare Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

INR 64 crore capex was spent in the first half of FY24, with approximately INR 52 crore invested in an upcoming Albumin manufacturing facility (Page 6).
The company is actively streamlining R&D expenditures and focusing on monetization to improve cash flow without compromising product quality (Page 2).
Investments have been made to upgrade API facilities to offer peptide, polymer, and CDMO services, aiming for value creation despite associated gestation periods (Page 2).
Ongoing strategic initiatives include scaling up complex product pipelines and extending existing products to new countries (Page 6).
Evaluation of strategic options including potential equity flows and repayments to reduce finance costs is underway, indicating future capital management efforts (Page 16).

Track Shilpa Medicare Ltd — get its next earnings analysis in your feed

How does Shilpa Medicare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisShilpa Medicare Ltd

Rev 3Mar 3

See where Shilpa Medicare Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Shilpa Medicare Ltd rank in Pharmaceuticals & Biotechnology?

Compare Shilpa Medicare Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Shilpa Medicare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Shilpa Medicare Ltd Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Shilpa Medicare Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Shilpa Medicare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season